These results suggest that virus-positive status may be a positive prognostic marker for patients undergoing ICI therapy for GC and HNSCC, which may be correlated with higher CD8 + T cell infiltration, T cell receptor clonal selection, and T cell exhaustion (for GC only). This evidence concerns the gene TBXT and head and neck squamous cell carcinoma.